Imunoterapija u tretmanu ne-sitnostaničnog raka pluća by Marko Jakopović et al.
60
REVIEW Libri Oncol. 2017;45(2-3):60–64
IMMUNOTHERAPY IN THE TREATMENT 
OF NON-SMALL CELL LUNG CANCER
MARKO JAKOPOVIĆ1,2, LELA BITAR1, KRISTINA KRPINA1, DAVORKA MURŠIĆ1, 
FRAN SEIWERTH1, MATEJA JANKOVIĆ1,2 and MIROSLAV SAMARŽIJA1,2
1 Department for Respiratory Diseaes Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia
2 School of Medicine, University of Zagreb, Zagreb, Croatia
Summary
Lung cancer is leading cause of death among malignant disease Worldwide and it is responsible for more than 1, 5 
million deaths each year. Lung cancer is divided in two major groups: non-small cell lung cancer (NSCLC) and small cell 
lung cancer (SCLC). Despite signifi cant improvements, for vast majority of patients chemotherapy still remains the treat-
ment of choice in the fi rst line sett ing. Progress over the last decade has led to the recognition of immunoevasion as of the 
leading hallmarks of cancer development. Clinical development was focused on immune checkpoint inhibitors, cytotoxic 
T-lymphocyte–associated antigen 4 (CTLA4) and programmed death (PD1/PD-L1) pathway. Programmed death 1 protein 
is another T-cell coinhibitory receptor with a structure similar to that of CTLA-4 but with a distinct biologic function and 
ligand specifi city and it is stimulated with PD-L1. PD-1 or PD-L1 blockade with drugs like nivolumab, pembrolizumab or 
atezolizumab resulted in superior eﬃ  cacy comparing to standard chemotherapy in fi rst-line sett ing. In patient with high 
PD-L1 expression (50% or more) pemborlizumab should be treatment of choice in fi rst-line sett ing. PD-L1 expression is at 
the moment only available biomarker who can predict response to immune checkpoint inhibitors. 
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IMUNOTERAPIJA U TRETMANU NE-SITNOSTANIČNOG RAKA PLUĆA
Sažetak
Karcinom pluća vodeći je uzrok smrti od malignih bolesti te je odgovoran za više od 1,5 milijuna smrti. U većine bole-
snika osnovu liječenja karcinoma pluća čini kemoterapija temeljena na platini. Unazad desetak godina, brojna se istraživanje 
provode o ulozi imunološkog sutava u karcinogenezi. Tumori uspjevaju izbjeći nadzor imunološkog sustava te tako rasti i 
metastazirati. Koncpet aktivacije imunološkog sutava iznimno je zanimljiv te se pokazalo da blokatori kontrolnih točaka 
pokazauju dobro učinkovitost u liječenju solidnih tumora poput melanoma ili bubrega. U zadnjih pet godina, inhibitori 
kontrolnih točaka nivolumab, pembrolizumab i atezoilizumab pokazali su se kao iznimno učinkoviti lijekovi u liječenju 
bolesnika s karcinomom pluća ranije liječenih klasičnom kemoterapijom. Pembrolizumab se također pokazao kao iznimno 
učinkovit u liječenju bolesnika sa visokom PD-L1 ekspresijom (PD-L1≥50%) u prvoj liniji liječenja. Ono što je nužno je pro-
naći biomarker koji bi ukazivao koji će bolesnici regirati na liječenje imunoterapijom. Danas znamo da što je viša ekspresija 
PD-L1 bolji je odgovor na imunoterapiju, ali i negativni bolesnici mogu odgovoriti na liječenje. Imunoterapija inhibitorima 
kontrolnih točaka danas je standard u drugoj liniji liječenja karcinoma pluća malih stanica, te je pembrolizumab najbolja 
opcija za liječenje visoko pozitivnih PD-L1 bolesnika u prvoj liniji liječenja. 




Lung cancer is leading cause of death among 
malignant disease worldwide and it is responsible 
for more than 1, 5 million deaths each year (1). In 
2012, lung cancer was the most common cancer 
and leading cause of cancer deaths among men, 
and leading cause of death among females in de-
veloped countries, and second most common 
cause of cancer deaths in less developed countries 
(1). In European Union there is a trend of decreas-
ing lung cancer mortality among men, and at the 
same time, increasing mortality was noticed 
among females (2). Lung cancer is divided in two 
major groups: non-small cell lung cancer (NSCLC) 
and small cell lung cancer (SCLC). NSCLC ac-
counts for around 85% of all cases, while incidence 
of SCLC is decreasing (3). NSCLC is further divid-
ed into adenocarcinoma, squamous carcinoma 
and large cell carcinoma; adenocarcinoma is the 
most common subtype of NSCLC. For decades, 
platinum based chemotherapy doublets were cor-
nerstone of treatment of advanced and metastatic 
NSCLC (4). During the last decade, discovery and 
introduction of targeted therapies for tumours 
harbouring activating mutations such are EGFR 
mutations and EML4-ALK translocation were a 
signifi cant step forward in treatment of lung can-
cer, but EGFR and ALK activating changes in the 
genome are present in around 20% of NSCLC pa-
tients (5,6). Despite signifi cant improvements, for 
vast majority of patients chemotherapy still re-
mains the treatment of choice in the fi rst line set-
ting. Therefore, further treatment options are 
needed to improve survival of patients with lung 
cancer. 
Immunotherapy
Progress over the last decade has led to the 
recognition of immunoevasion as of the leading 
hallmarks of cancer development. Cancer cells are 
thought to escape immune destruction by dis-
abling components of the immune system that are 
suppose to eliminate them (7). Tumor immune es-
cape mechanisms include the loss of major histo-
compatibility complex antigen (HLA) expression, 
activation of regulatory T cells, upregulation of 
immune checkpoints and immunosuppressive cy-
tokines (8). Therefore, activation of the immune 
system against cancer represents an att ractive 
treatment approach. However, until recently, anti-
tumor eﬀ ects of immunotherapy among solid tu-
mors were limited to melanoma, renal and pros-
tate cancers (9).
The goal of immunotherapy is the induction 
of a humoral or cellular immune response against 
cancer. Clinical development of immunotherapy 
for NSCLC has involved three broad classes of 
agents: nonspecifi c immune stimulants, vaccines 
and immune checkpoint inhibitors (9).
Unfortunately, vaccines and nonspecifi c im-
mune stimulants did not show eﬃ  cacy in lung 
cancer patients. Clinical development was then 
focused on immune checkpoint inhibitors, cyto-
toxic T-lymphocyte–associated antigen 4 (CTLA4) 
and programmed death (PD1/PD-L1) pathway.
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) 
protein is expressed on the surface of T cells. It is 
acting as suppressor of T-cell activation by com-
peting with CD28 for B7 binding in an inhibitory 
fashion. CTLA-4 inhibitors are among the earliest 
immune checkpoint inhibitors in clinical develop-
ment. Antibodies to CTLA-4 block the inhibition 
of CD28/B7 T-cell activation and stimulate anti-
tumour activity (10). Ipilimumab, a fully human-
ized monoclonal antibody that binds to CTLA-4 
and prevents it from binding to its ligand, was 
tested in combination with chemotherapy on 
phase II trial in patients with NSCLC (11). Combi-
nation treatment improved progression-free sur-
vival (PFS) compared to chemotherapy alone. Bet-
ter responses were seen in patients with squamous 
cell carcinoma, so this subgroup was selected for 
phase III trial (11). Unfortunately, phase III trial 
was stopped prematurely due to detrimental ef-
fect of combination of ipilimumab and chemo-
therapy compared to chemotherapy alone.
Programmed death 1 protein is another T-
cell coinhibitory receptor with a structure similar 
to that of CTLA-4 but with a distinct biologic func-
tion and ligand specifi city and it is stimulated 
with PD-L1 (12). Interrupting this pathway, either 
by blocking PD-1 or by blocking PD-L1, showed 
excellent results.
Nivolumab is fully human, PD-L1–specifi c, 
IgG monoclonal antibody that inhibits the binding 
of PD-L1 to both PD-1 and CD80 (13). It was fi rst 
tested in phase I trial in diﬀ erent tumor types, in-
cluding NSCLC. In heavily pretreated adenocarci-
noma and squamous cell carcinoma patients, ob-
jective response rates of 8% and 16%, respectively, 
were noticed (12). Promising results of phase I 
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trial lead to starting phase III trials in second-line 
treatment of nivolumab against docetaxel.
CheckMate – 024 was phase III trial which 
compared eﬃ  cacy of nivolumab against docetaxel 
in patients with squamous cell lung cancer who 
progressed after fi rst-line standard platinum- 
based doublet. Novolumab signifi cantly im-
proved PFS (3.5 months with nivolumab versus 
2.8 months with docetaxel (hazard ratio, HR) for 
death or disease progression, 0.62; 95% CI, 0.47 to 
0.81; P<0.001). What was more important, nivo-
lumab signifi cantly improved overall survival 
(OS) to 9.2 months with nivolumab versus 6.0 
months with docetaxel. The risk of death was 41% 
lower with nivolumab than with docetaxel (haz-
ard ratio, 0.59; 95% CI, 0.44 to 0.79; P<0.001) (14).
Similarly, CheckMate-057 phase III was con-
ducted in patients with non-sqamous NSCLC. In-
terestingly, PFS did not favor nivolumab over 
docetaxel (mPFS 2.3months vs 4.2 months), the 
rate of progression-free survival at 1 year was 
higher with nivolumab than with docetaxel (19% 
and 8%, respectively). Overall survival was longer 
with nivolumab than with docetaxel. The median 
overall survival was 12.2 months in patients tretat-
ed with nivolumab and 9.4 months in patients 
treated with docetaxel (hazard ratio for death, 
0.73; 96% CI, 0.59 to 0.89; P=0.002) (15). Positive re-
sults of this two trials has lead to approval in USA 
and Europe of nivolumab in patients with either 
squamous or non-squamous cell lung cancer in 
patients who progressed after fi rst-line treatment.
Pembrolizumab, a highly selective, human-
ized monoclonal IgG4 kappa isotype antibody 
against PD-1 was tested in a large phase I (495 pa-
tients) KeyNote 001 in NSCLC patients. The medi-
an PFS was 3.7 months, and the median OS was 
12.0 months. Among patients with a proportion 
score of at least 50% in the validation group, the 
response rate was 45.2%. Among all the patients 
with a proportion score of at least 50%, median PFS 
was 6.3 months; median OS was not reached (16).
KeyNote – 010 was large phase III trial which 
compared pembrolizumab to docetaxel in second-
line treatment of patients with NSCLC who are 
showed PD-L1 positivity of 1 or more percent. 
Two doses of pembrolizumab, 2 mg/kg and 10 
mg/kg were tested. Both doses showed signifi cant 
improvement in PFS and OS compared to docetax-
el. There was no signifi cant diﬀ erence between 
diﬀ erent doses of pembrolizumab, so dose of 2 
mg/kg was registered in USA and Europe for sec-
ond-line treatment of PD-L1 (PD-L1≥1) positive 
patients with NSCLC (17).
Atezolizumab, a humanised anti-program-
med death-ligand 1 (PD-L1) monoclonal antibody 
that inhibits PD-L1 and programmed death-1 
(PD-1) and PD-L1 and B7-1 interactions was tested 
in phase III OAK trial against docetaxel in second-
line sett ing in patients with NSCLC previously 
treated with standard chemotherapy. Overall sur-
vival was improved with atezolizumab compared 
with docetaxel (medianOS was 13·8 months vs 9·6 
months; hazard ratio [HR] 0·73, p=0·0003). Results 
of this trial have lead to approval of atezolizumab 
regardless of PD-L1 expression in second-line set-
ting of NSCLC patients. 
First line-sett ing
Promising and encouraging results of sec-
ond-line trials gave a lot of enthusiasm to investi-
gators and two large phase III trial in PD-L1 high-
ly positive NSCLC patients were conducted (18).
Pembrolizumab was investigated in fi rst-line 
sett ing against standard platinum-based chemo-
therapy in phase III KeyNote-024 trial in highly 
(PD-L1≥50%) positive patients. Median progres-
sion-free survival was 10.3 months in the pembro-
lizumab group versus 6.0 months in the chemo-
therapy group (hazard ratio for disease progres-
sion or death, 0.50; 95% CI, 0.37 to 0.68; P<0.001). 
The estimated rate of overall survival at 6 months 
was 80.2% in the pembrolizumab group versus 
72.4% in the chemotherapy group (hazard ratio 
for death, 0.60; 95% CI, 0.41 to 0.89; P=0.005). The 
response rate was higher in the pembrolizumab 
group than in the chemotherapy group (44.8% vs. 
27.8%). These astonishing results resulted in ap-
proval of pembrolizumab in fi rst-line sett ing in 
highly (PD-L1≥50%) positive treatment – naïve 
NSCLC patients (19).
Similary designed CheckMate – 026 phase III 
trial compared nivolumab and standard chemo-
therapy in fi rst-line sett ing in highly positive (PD-
L1≥10%, diﬀ erent test and cut-oﬀ  values used). 
The trial was negative with no statistical signifi -
cant diﬀ erence in OS (mOS 14.4 months with 
nivolumab (20). 
PD-L1 expression
In patients with activating mutations like 
EGFR and ALK, molecular diagnostics of these 
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changes is crucial for selection of patients who are 
candidates for targeted treatments. In patients 
who harbour activating mutation treatment with 
targeted agents’ like EGFR tyrosine kinase inhibi-
tos or ALK inhibitors can prolong PFS and even 
OS (5,6). A search for biomarker who can predict 
long-term responders is ongoing. From phase III 
trial we know that 20-30% of all patients have du-
rable and ongoing responses to immunotherapy 
treatment (14,15,17,18). At the moment, we are not 
quite sure what the best biomarkers which could 
predict response to immunotherapy agents are. 
Currently, the best biomarker we have is PD-L1. 
PD-L1 expression can predict response to immune 
checkpoint inhibitors. The higher expression is, 
the bett er is response to the treatment (14,15,
16,17,18). Still, there are patients who benefi t from 
treatment with immune check point inhibitors de-
spite they are PD-L1 negative (15,18). That means 
that PD-L1 is not the most appropriate biomarker 
but at the moment is the best we have. 
CONCLUSION
Progress over the last decade has led to the 
recognition of immunoevasion as of the leading 
hallmarks of cancer development. However, until 
recently, antitumor eﬀ ects of immunotherapy 
among solid tumors were limited to melanoma, 
renal and prostate cancers. Recent achivemtns 
have shown that immunotherapy has promising 
results in patients with non-small cell lung cancer. 
Immune checkpoint inhibitors which bloc either 
PD-1 or PD-L1 like nivolumab, pembrolizumab 
and atezolizumab showed superiority over che-
motherapy in second-line sett ing. Whereas, 
nivolumab and atezolizumab are approved in sec-
ond-line sett ing in treatment of NSCLC regardless 
of PD-L1 status, pembrolizumab is approved in 
second-line sett ing in patients who are PD-L1≥1% 
positive(21). In fi rst line-sett ing, pembrolizumab 
is treatment of choice in NSCLC patients who are 
PD-L1≥postive and at the same time EGFR, ALK 
and ROS1 negative (23).
Immune checkpoint inhibitors oﬀ ers a new 
hope to non-small cell lung cancer patients and 
combinations of immunotherapy and other treat-
ment approaches like chemotherapy, radiothera-
py and targeted agents are under investigation. 
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